This trial is testing if adding the drug pembrolizumab to cell therapy, which takes young tumor infiltrating lymphocytes (TIL) cells from a person's tumors and grows them in a lab, is safe and effective to shrink melanoma tumors.
2 Primary · 2 Secondary · Reporting Duration: 30 days after end of treatment
Experimental Treatment
170 Total Participants · 4 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18 - 70 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: